Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.41 |
| ▸ | CDK4 | P11802 | 2/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCND2 | P30279 | 1/20 | 0.40 |
| ▸ | CCND3 | P30281 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19690913 | 0.88 | HTT (0.48) | BPTFTSHRNPSR1GBA1ADORA2A | |
| SCHEMBL19690912 | 0.85 | BPTF (0.43) | BPTFTSHRNPSR1GBA1ADORA2A | |
| SCHEMBL19690876 | 0.85 | AURKA (0.48) | BPTFTSHRNPSR1GBA1ADORA2A | |
| SCHEMBL19690934 | 0.84 | ADORA2A (0.56) | BPTFTSHRNPSR1GBA1ADORA2A | |
| SCHEMBL19690893 | 0.84 | AURKA (0.47) | BPTFTSHRNPSR1GBA1ADORA2A | |
| SCHEMBL19690986 | 0.82 | GBA1 (0.44) | BPTFTSHRNPSR1GBA1ADORA2A | |
| SCHEMBL19691074 | 0.81 | AURKA (0.48) | GBA1SMN1; SMN2AURKAEGFRSYK | |
| SCHEMBL19690977 | 0.79 | CTSC (0.50) | SMN1; SMN2USP2CREBBP | |
| SCHEMBL19690860 | 0.77 | HTT (0.43) | TSHRNPSR1GBA1ADORA2AALK | |
| SCHEMBL19691065 | 0.77 | HTT (0.43) | GBA1ADORA2AALKADORA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | BPTF 3505/4885TSHR 2859/4885NPSR1 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.